611 related articles for article (PubMed ID: 20570444)
21. Mechanisms of tumor resistance to small-molecule vascular disrupting agents: treatment and rationale of combination therapy.
Wu XY; Ma W; Gurung K; Guo CH
J Formos Med Assoc; 2013 Mar; 112(3):115-24. PubMed ID: 23473523
[TBL] [Abstract][Full Text] [Related]
22. Platelet-Membrane-Coated Nanoparticles Enable Vascular Disrupting Agent Combining Anti-Angiogenic Drug for Improved Tumor Vessel Impairment.
Li B; Chu T; Wei J; Zhang Y; Qi F; Lu Z; Gao C; Zhang T; Jiang E; Xu J; Xu J; Li S; Nie G
Nano Lett; 2021 Mar; 21(6):2588-2595. PubMed ID: 33650872
[TBL] [Abstract][Full Text] [Related]
23. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
Head M; Jameson MB
Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic targeting of the tumor vasculature.
Tozer GM; Bicknell R
Semin Radiat Oncol; 2004 Jul; 14(3):222-32. PubMed ID: 15254865
[TBL] [Abstract][Full Text] [Related]
25. Vascular damaging agents.
Patterson DM; Rustin GJ
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):443-56. PubMed ID: 17459681
[TBL] [Abstract][Full Text] [Related]
26. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.
De Bock K; Cauwenberghs S; Carmeliet P
Curr Opin Genet Dev; 2011 Feb; 21(1):73-9. PubMed ID: 21106363
[TBL] [Abstract][Full Text] [Related]
27. Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth.
Pérez-Pérez MJ; Priego EM; Bueno O; Martins MS; Canela MD; Liekens S
J Med Chem; 2016 Oct; 59(19):8685-8711. PubMed ID: 27348355
[TBL] [Abstract][Full Text] [Related]
28. Anti-vascular nano agents: a promising approach for cancer treatment.
Chen D; Qu X; Shao J; Wang W; Dong X
J Mater Chem B; 2020 Apr; 8(15):2990-3004. PubMed ID: 32211649
[TBL] [Abstract][Full Text] [Related]
29. Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics.
Gill JH; Rockley KL; De Santis C; Mohamed AK
Pharmacol Ther; 2019 Oct; 202():18-31. PubMed ID: 31173840
[TBL] [Abstract][Full Text] [Related]
30. Advanced Chemoembolization by Anti-angiogenic Calcium-Phosphate Ceramic Microspheres Targeting the Vascular Heterogeneity of Cancer Xenografts.
Emoto M; Yoshihisa H; Yano K; Choijamts B; Tsugu H; Tachibana K; Aizawa M
Anticancer Res; 2015 Sep; 35(9):4757-64. PubMed ID: 26254366
[TBL] [Abstract][Full Text] [Related]
31. [Angiogenesis inhibitors and radiotherapy].
Riesterer O
Praxis (Bern 1994); 2012 Aug; 101(16):1031-7. PubMed ID: 22878946
[TBL] [Abstract][Full Text] [Related]
32. ASA404: update on drug development.
Rehman F; Rustin G
Expert Opin Investig Drugs; 2008 Oct; 17(10):1547-51. PubMed ID: 18808313
[TBL] [Abstract][Full Text] [Related]
33. Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data.
DuBois SG; Marina N; Glade-Bender J
Cancer; 2010 Feb; 116(3):749-57. PubMed ID: 20029966
[TBL] [Abstract][Full Text] [Related]
34. Escape mechanisms after antiangiogenic treatment, or why are the tumors growing again?
Hlushchuk R; Makanya AN; Djonov V
Int J Dev Biol; 2011; 55(4-5):563-7. PubMed ID: 21858777
[TBL] [Abstract][Full Text] [Related]
35. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
36. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization.
Fukumura D; Jain RK
Microvasc Res; 2007; 74(2-3):72-84. PubMed ID: 17560615
[TBL] [Abstract][Full Text] [Related]
37. Smart Nanotherapeutic Targeting of Tumor Vasculature.
Li Z; Di C; Li S; Yang X; Nie G
Acc Chem Res; 2019 Sep; 52(9):2703-2712. PubMed ID: 31433171
[TBL] [Abstract][Full Text] [Related]
38. Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery.
Cooney MM; van Heeckeren W; Bhakta S; Ortiz J; Remick SC
Nat Clin Pract Oncol; 2006 Dec; 3(12):682-92. PubMed ID: 17139319
[TBL] [Abstract][Full Text] [Related]
39. AVE8062: a new combretastatin derivative vascular disrupting agent.
Delmonte A; Sessa C
Expert Opin Investig Drugs; 2009 Oct; 18(10):1541-8. PubMed ID: 19758109
[TBL] [Abstract][Full Text] [Related]
40. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.
Kanthou C; Tozer GM
Int J Exp Pathol; 2009 Jun; 90(3):284-94. PubMed ID: 19563611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
